A trial to evaluate the efficacy and safety of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) therapy on height velocity (Ht-V) in patients with idiopathic short stature in Korea

Registry ID

EUCTR2015-002613-30

Source registry

EUCTR

Phase

PHASE3

Sponsor

Novo Nordisk A/S

Last update

2026-08-16

Conditions

• Idiopathic short stature

Summary

To evaluate the efficacy of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) therapy compared with untreated group assessed by height velocity after 6 months of treatment in patients with idiopathic short stature (ISS) in Korea

View on source registry